OPEN END TURBO OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 20:56:41 02/07/2024 BST | ||
| 8.21 EUR | -2.84% |
|
| Current month | -2.87% | ||
| 1 month | -17.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 02/07/24 | 8.21 | -2.84% |
| 01/07/24 | 8.45 | -2.87% |
| 28/06/24 | 8.7 | +5.71% |
| 27/06/24 | 8.23 | -1.08% |
| 26/06/24 | 8.32 | -0.12% |
Delayed Quote Börse Stuttgart
Last update July 02, 2024 at 08:56 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB4XMQ |
| ISIN | DE000JB4XMQ2 |
| Date issued | 18/10/2023 |
| Strike | 561.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 17.84 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.94 € |
|---|---|
| Lowest since issue | 7.04 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
473.8
USD
Average target price
468.3
USD
Spread / Average Target
-1.16%
- Stock Market
- Certificates
- Certificat
